TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
+3.24%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -37.5%
- EBIT
- +4.1%
- EPS
- +78.9%
- Free cash flow
- +27.6%
- Operating cash flow
- +27.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +37.8%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +71.1%
- EBIT
- +52.0%
- Net income
- +74.3%
- EPS
- +94.7%
- Free cash flow
- +62.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026